Clinical Trials for Other Solid Tumor

A Randomized Study of Two Dosing Regimens of Adagrasib in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial involves adult patients with advanced or metastatic non-small cell lung cancer harboring the KRAS G12C mutation who have previously been treated with platinum-based chemotherapy and immune checkpoint inhibitors, assessing two dosing regimens of adagrasib, an oral covalent inhibitor targeting the KRAS G12C mutation.

ClinicalTrials.gov ID: NCT05853575

A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 as Monotherapy and in Combination With Toripalimabin Subjects With Advanced Solid Malignancies Including Lymphoma

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: The trial is enrolling adults with advanced, unresectable, or metastatic solid tumors, including lymphoma, who have progressed after prior treatments, to evaluate the safety and tolerability of TAB004, a monoclonal antibody targeting BTLA, as monotherapy and in combination with toripalimab, an anti-PD-1 antibody.

ClinicalTrials.gov ID: NCT04137900

A Phase 1 Study of SGN-B6A in Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial assesses the safety and efficacy of sigvotatug vedotin, an investigational drug targeting integrin beta-6, alone and combined with pembrolizumab and chemotherapy, in patients with various advanced solid tumors like NSCLC, head and neck cancer, and HER2-negative breast cancer. It includes participants either treatment-naïve or those who have relapsed from standard therapies, in a non-randomized, dose-escalation and expansion design.

ClinicalTrials.gov ID: NCT04389632

A Phase II Trial of Cemiplimab Alone for Untreated Brain Metastases From PD-L1 ≥ 50% Non-Small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial involves patients aged 18 and older with advanced non-small cell lung cancer (NSCLC) exhibiting PD-L1 expression levels ≥ 50%, who have untreated brain metastases measuring 5-15 mm and no EGFR, ALK, or ROS1 aberrations, and evaluates the efficacy of cemiplimab, a PD-1 blocking monoclonal antibody, administered as monotherapy without upfront radiation.

ClinicalTrials.gov ID: NCT05840770

Phase II Study of Adagrasib + Stereotactic Radiosurgery (SRS) for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial involves 30 adult patients with stage IV KRAS G12C-mutated NSCLC and untreated brain metastases, assessing the efficacy of combination treatment with the KRAS G12C inhibitor adagrasib and Stereotactic Radiosurgery (SRS).

ClinicalTrials.gov ID: NCT06248606

An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination, in Patients With Advanced Solid/Metastatic Tumours.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial targets patients with advanced or metastatic tumors, including metastatic castration-resistant prostate cancer, metastatic breast cancer, and non-small cell lung cancer, evaluating CCS1477, an inhibitor of bromodomains of p300/CBP, both as monotherapy and in combination with therapies like abiraterone and atezolizumab.

ClinicalTrials.gov ID: NCT03568656

A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Subjects With Selected Tumor Types

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: The trial enrolls adults with measurable ovarian, endometrial, triple-negative breast, or non-small cell lung cancers to evaluate the safety and efficacy of Farletuzumab Ecteribulin (MORAb-202), an antibody-drug conjugate targeting folate receptor alpha, which delivers eribulin to cancer cells.

ClinicalTrials.gov ID: NCT04300556

ICON-RT: Intracranial Consolidation and Deferral of Radiation Therapy in Patients Receiving Approved CNS-Active Systemic Therapeutics

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial involves patients aged 18 and older with EGFR-mutant NSCLC and measurable brain metastases, examining the efficacy of osimertinib, a CNS-penetrant EGFR TKI, with or without stereotactic radiosurgery (SRS). Participants may be TKI-naïve or have started TKI treatment within the past three months.

ClinicalTrials.gov ID: NCT06741085

Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-small Cell Lung Cancers (RadiaNCe Lung X)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: The trial involves treatment-naïve adults with metastatic non-small cell lung cancer featuring actionable driver mutations, using radiation therapy on the primary lung lesion followed by tyrosine kinase inhibitor (TKI) therapy to delay disease progression. Radiation doses range from 24-60 Gy, and TKI treatment targets genetic mutations driving cancer growth.

ClinicalTrials.gov ID: NCT06305715

A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial evaluates the efficacy of sotorasib targeting KRAS p.G12C in combination with carboplatin and pemetrexed, compared to pembrolizumab with the same chemotherapy regimen, for treatment-naive patients with stage IV or advanced stage IIIB/C nonsquamous NSCLC with KRAS p.G12C mutations and no PD-L1 expression.

ClinicalTrials.gov ID: NCT05920356